Clinical evaluation of choline magnesium trisalicylate in rheumatoid arthritis.

Twenty-three patients with rheumatoid arthritis were given choline magnesium trisalicylate (CMT) (Trilisate; Adcock-Ingram) in a dose of 1.5 g (3 tablets) twice daily and were followed up for 6 weeks. Nineteen patients completed the study and the data obtianed were subjected to statistical analysis. There was a statistically significant improvement in the indices of inflammation. Seven patients developed tinnitus, which resolved on reduction of the dose to 1 g (2 tablets) twice daily. Four patients developed pruritus and minor gastro-intestinal side-effects were present in 3 patients, but all these side-effects were transient and no change in therapy was necessary.